Pharma companies continue to strive for tight control of critical quality attributes (CQAs). When Ferring Pharmaceuticals wanted to move from batch to continuous manufacturing, they found that laboratory assays were too time consuming to provide meaningful feedback for real-time control, and 100% product quality inspection was not possible.